valproic acid has been researched along with Leukemia in 20 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a phase 1/2 study of the combination of 5-aza-2'-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia, including older untreated patients." | 9.12 | Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. ( Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Fiorentino, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; Koller, C; O'brien, S; Ravandi, F; Rosner, G; Rytting, M; Sanchez-Gonzalez, B; Verstovsek, S; Wierda, WG; Xiao, L; Yang, H, 2006) |
| "Our results suggested that the novel combination of oridonin plus VPA exerted synergistic antiproliferative and apoptosis-inducing effects on human myeloid leukemia cells, and may serve as a potentially promising antileukemia strategy." | 7.91 | Synergistic antitumor activity of oridonin and valproic acid on HL-60 leukemia cells. ( Li, W; Ma, L, 2019) |
| "Combination of HDACi with etoposide can have a synergistic effect on increased apoptosis in leukemia cells but this effect depends on the cancer cell type and other factors such as the concentration of drugs and the administration schedule." | 7.78 | Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells. ( Jasek, E; Jasinska, M; Jurkowska, H; Lis, GJ; Litwin, JA, 2012) |
| "Arsenic trioxide (ATO) is an effective therapeutic agent for acute promyelocytic leukemia (APL) and other hematopoietic malignancies." | 7.76 | Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines. ( Jiang, J; Liu, XS; Peng, CY; Zheng, HT, 2010) |
| "We investigated the effects of valproic acid (VPA) on the growth and survival of human leukemia cell lines." | 7.71 | Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. ( Kawagoe, H; Kawagoe, R; Sano, K, 2002) |
| "Valproic acid has been previously associated with hematologic toxicity, including a reversible myelodysplasia-like syndrome without chromosomal abnormalities." | 5.33 | Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis? ( Bair, AK; Coyle, TE; Mehdi, S; Stein, C; Vajpayee, N; Wright, J, 2005) |
| "We conducted a phase 1/2 study of the combination of 5-aza-2'-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia, including older untreated patients." | 5.12 | Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. ( Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Fiorentino, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; Koller, C; O'brien, S; Ravandi, F; Rosner, G; Rytting, M; Sanchez-Gonzalez, B; Verstovsek, S; Wierda, WG; Xiao, L; Yang, H, 2006) |
| "Two demethylating agents are approved in myelodysplastic syndromes (MDS): 5-azacitidine and 5-aza-2'-deoxycitidine (decitabine)." | 4.84 | Demethylating agents in myeloid malignancies. ( Garcia-Manero, G, 2008) |
| "Our results suggested that the novel combination of oridonin plus VPA exerted synergistic antiproliferative and apoptosis-inducing effects on human myeloid leukemia cells, and may serve as a potentially promising antileukemia strategy." | 3.91 | Synergistic antitumor activity of oridonin and valproic acid on HL-60 leukemia cells. ( Li, W; Ma, L, 2019) |
| "Combination of HDACi with etoposide can have a synergistic effect on increased apoptosis in leukemia cells but this effect depends on the cancer cell type and other factors such as the concentration of drugs and the administration schedule." | 3.78 | Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells. ( Jasek, E; Jasinska, M; Jurkowska, H; Lis, GJ; Litwin, JA, 2012) |
| " We found that 4 histone deacetylase inhibitors, trichostatin A (TSA), sodium butyrate (SB), valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA), all significantly induced EBV lytic cycle in EBV-positive gastric carcinoma cells (AGS/BX1, latency II) but only weakly induced in Burkitt lymphoma cells (AK2003, latency I) and did not induce in lymphoblastoid cells (LCLs, latency III)." | 3.76 | Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. ( Chiang, AK; Hui, KF, 2010) |
| "Arsenic trioxide (ATO) is an effective therapeutic agent for acute promyelocytic leukemia (APL) and other hematopoietic malignancies." | 3.76 | Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines. ( Jiang, J; Liu, XS; Peng, CY; Zheng, HT, 2010) |
| "To study the reactivation of retinoic acid receptor beta (RARbeta) expression in myeloid leukemia cells by a combination of all-trans retinoic acid (ATRA) with a DNA demethylating agent, decitabine (DAC), and valproic acid (VPA, a histone deacetylase inhibitor),and their effects on cell differentiation and proliferation." | 3.74 | [Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell]. ( Ai, GW; Liu, W; Ma, XX; Meng, XQ; Meng, YS; Wei, R; Zhang, YX, 2007) |
| "We investigated the effects of valproic acid (VPA) on the growth and survival of human leukemia cell lines." | 3.71 | Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. ( Kawagoe, H; Kawagoe, R; Sano, K, 2002) |
| "Valproic acid has been previously associated with hematologic toxicity, including a reversible myelodysplasia-like syndrome without chromosomal abnormalities." | 1.33 | Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis? ( Bair, AK; Coyle, TE; Mehdi, S; Stein, C; Vajpayee, N; Wright, J, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Güneş, H | 1 |
| Acıpayam, C | 1 |
| Akgüngör, F | 1 |
| Kütükçü, M | 1 |
| Li, W | 1 |
| Ma, L | 1 |
| Shi, M | 1 |
| Ren, X | 1 |
| Wang, X | 1 |
| Wang, H | 1 |
| Liu, G | 1 |
| Yuan, X | 1 |
| Zheng, S | 1 |
| Yu, L | 1 |
| Pan, S | 1 |
| Song, G | 1 |
| Guo, Q | 1 |
| Li, L | 1 |
| Zhang, X | 1 |
| Zhang, Z | 1 |
| Ding, H | 1 |
| Jiang, G | 1 |
| Arulmozhivarman, G | 1 |
| Stöter, M | 1 |
| Bickle, M | 1 |
| Kräter, M | 1 |
| Wobus, M | 1 |
| Ehninger, G | 1 |
| Stölzel, F | 1 |
| Brand, M | 1 |
| Bornhäuser, M | 1 |
| Shayegi, N | 1 |
| Pulliam, SR | 1 |
| Pellom, ST | 1 |
| Shanker, A | 1 |
| Adunyah, SE | 1 |
| Lam, YM | 1 |
| Chan, YF | 1 |
| Chan, LC | 1 |
| Ng, RK | 1 |
| Garcia-Manero, G | 3 |
| Gul, H | 1 |
| Marquez-Curtis, LA | 1 |
| Jahroudi, N | 1 |
| Larratt, LM | 1 |
| Janowska-Wieczorek, A | 1 |
| Hui, KF | 1 |
| Chiang, AK | 1 |
| Peng, CY | 1 |
| Jiang, J | 1 |
| Zheng, HT | 1 |
| Liu, XS | 1 |
| Zhang, XZ | 1 |
| Yin, AH | 1 |
| Lin, DJ | 1 |
| Zhu, XY | 1 |
| Ding, Q | 1 |
| Wang, CH | 1 |
| Chen, YX | 1 |
| Jasek, E | 1 |
| Lis, GJ | 1 |
| Jasinska, M | 1 |
| Jurkowska, H | 1 |
| Litwin, JA | 1 |
| Sakajiri, S | 1 |
| Kumagai, T | 1 |
| Kawamata, N | 1 |
| Saitoh, T | 1 |
| Said, JW | 1 |
| Koeffler, HP | 1 |
| Coyle, TE | 1 |
| Bair, AK | 1 |
| Stein, C | 1 |
| Vajpayee, N | 1 |
| Mehdi, S | 1 |
| Wright, J | 1 |
| Sanchez-Gonzalez, B | 2 |
| Yang, H | 2 |
| Bueso-Ramos, C | 2 |
| Hoshino, K | 1 |
| Quintas-Cardama, A | 1 |
| Richon, VM | 1 |
| Kantarjian, HM | 1 |
| Rosner, G | 1 |
| Verstovsek, S | 1 |
| Rytting, M | 1 |
| Wierda, WG | 1 |
| Ravandi, F | 1 |
| Koller, C | 1 |
| Xiao, L | 1 |
| Faderl, S | 1 |
| Estrov, Z | 1 |
| Cortes, J | 1 |
| O'brien, S | 1 |
| Estey, E | 1 |
| Fiorentino, J | 1 |
| Jabbour, E | 1 |
| Issa, JP | 1 |
| Sasaki, K | 1 |
| Yamagata, T | 1 |
| Mitani, K | 1 |
| Meng, YS | 1 |
| Ma, XX | 1 |
| Meng, XQ | 1 |
| Wei, R | 1 |
| Liu, W | 1 |
| Ai, GW | 1 |
| Zhang, YX | 1 |
| Kawagoe, R | 1 |
| Kawagoe, H | 1 |
| Sano, K | 1 |
| Tittle, TV | 1 |
| Schaumann, BA | 1 |
| Rainey, JE | 1 |
| Taylor, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Clinical Evaluation of Vorinostat Combined With Salvage Reinduction Chemotherapy Including Gemtuzumab Ozogamicin, Idarubicin and Cytarabine and Vorinostat Maintenance in Relapse or Refractory Acute Myeloid Leukemia Patients With 50 Years or Older[NCT01039363] | Phase 2 | 27 participants (Anticipated) | Interventional | Not yet recruiting | |||
| Phase I/II Study of 5-aza-2'-Deoxycytidine and Valproic Acid in Patients With Relapsed/Refractory Leukemia or Myelodysplastic Syndromes[NCT00075010] | Phase 1/Phase 2 | 54 participants (Actual) | Interventional | 2004-01-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for valproic acid and Leukemia
| Article | Year |
|---|---|
Demethylating agents in myeloid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; D | 2008 |
1 trial available for valproic acid and Leukemia
| Article | Year |
|---|---|
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; Decit | 2006 |
18 other studies available for valproic acid and Leukemia
| Article | Year |
|---|---|
Leukemia-like megaloblastic anemia in an autistic child receiving risperidone and valproic acid.
Topics: Anemia, Megaloblastic; Autistic Disorder; Child; Humans; Leukemia; Risperidone; Valproic Acid; Vitam | 2020 |
Synergistic antitumor activity of oridonin and valproic acid on HL-60 leukemia cells.
Topics: Apoptosis; Diterpenes, Kaurane; Drug Synergism; HL-60 Cells; Humans; Leukemia; Signal Transduction; | 2019 |
A novel combination of oridonin and valproic acid in enhancement of apoptosis induction of HL-60 leukemia cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Prolife | 2016 |
In Vivo Chemical Screen in Zebrafish Embryos Identifies Regulators of Hematopoiesis Using a Semiautomated Imaging Assay.
Topics: Animals; Cell Lineage; Hematopoiesis; Hematopoietic Stem Cells; High-Throughput Screening Assays; Hu | 2016 |
Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Butyrates; Caspase 3; Cell Line; Cell Line, Tumor; Cell Mo | 2016 |
Histone deacetylase inhibitors induce leukemia gene expression in cord blood hematopoietic stem cells expanded ex vivo.
Topics: Cell Culture Techniques; Cells, Cultured; Fetal Blood; Gene Expression Regulation, Leukemic; Hematop | 2017 |
Valproic acid exerts differential effects on CXCR4 expression in leukemic cells.
Topics: Antigens, CD34; Cell Differentiation; Chemotaxis; Gene Expression Regulation, Leukemic; HL-60 Cells; | 2010 |
Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Burkitt Lymphoma; Butyrates; Carcinoma; Cell Cy | 2010 |
Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Proliferation; Cell Survival; | 2010 |
Analyzing gene expression profile in K562 cells exposed to sodium valproate using microarray combined with the connectivity map database.
Topics: Apoptosis; Databases, Factual; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitor | 2012 |
Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Caspase 7; Drug Synergism; Eto | 2012 |
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation | 2005 |
Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis?
Topics: Acute Disease; Adult; Anticonvulsants; Chromosome Aberrations; Chromosomes, Human, Pair 7; Chromosom | 2005 |
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
Topics: Acetylation; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2006 |
Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cor | 2008 |
[Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].
Topics: Acetylation; Adult; Aged; Azacitidine; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA M | 2007 |
Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Caspases; Cytochrome c Group; Dose-Response Relationship | 2002 |
Segregation of the growth slowing effects of valproic acid from phenytoin and carbamazepine on lymphoid tumor cells.
Topics: Carbamazepine; Cell Division; Culture Techniques; Humans; Kinetics; Leukemia; Lymphoma; Phenytoin; R | 1992 |